MaxCyte Inc.
Stock Exchange London Stock Exchange
EPS
GBP0.13
Market Cap
GBP66.73 M
Shares Outstanding
51.33 M
Public Float
-

Profile

Address
22 Firstfield Road
Gaithersburg Maryland 20878
United States
Employees -
Website http://www.maxcyte.com
Updated 07/08/2019
MaxCyte, Inc. enages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include MaxCyte STX, MaxCyte VLX, and MaxCyte GT.

Financials

View All

Douglas A. Doerfler
President, Chief Executive Officer & Director
Ronald E. Holtz
CFO, Secretary & Executive Director